Core Insights - Kyowa Kirin, Inc. announced new clinical study data on mogamulizumab for treating relapsed or refractory mycosis fungoides and Sézary syndrome, which will be presented at the ASH 2025 annual meeting [1][3] Clinical Study Findings - The presentations will cover mogamulizumab's therapeutic benefits, safety, pharmacodynamic profile, alternative dosing strategies, real-world treatment patterns, and biomarker-associated outcomes [2][3] - A Phase 2 study will assess a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome [4] - An integrated analysis will investigate longitudinal effects between responders and non-responders in mogamulizumab trials for mature T-cell lymphomas [4] - Real-world usage of mogamulizumab as monotherapy and in combination among patients with mycosis fungoides or Sézary syndrome in the U.S. will also be presented [4] Company Overview - Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company focused on drug discovery and biotechnology innovation for over 70 years, aiming to develop novel medicines for high unmet medical needs [12]